Premium
Effect of rifampicin and isoniazid on vitamin D metabolism
Author(s) -
Brodie Martin J,
Boobis Alan R,
Hillyard Carmel J,
Abeyasekera Gamini,
Stevenson John C,
MacIntyre Ian,
Park B Kevin
Publication year - 1982
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1982.197
Subject(s) - rifampicin , isoniazid , pharmacology , medicine , niacin , ethambutol , metabolism , tuberculosis , pathology
Rifampicin, 600 mg, and isoniazid, 300 mg daily for 14 days, reduced circulating levels of 25‐hydroxy vitamin D (25‐OHD) and 1α, 25‐dihydroxy vitamin D (1,25(OH) 2 D) by 34% (P < 0.01) and 23% (P < 0.05) in eight healthy subjects. This was accompanied by a rise in parathyroid hormone (PTH) of 57% (P < 0.01), but not by a fall in serum calcium or phosphate levels. There was induction of endogenous cortisol oxidation in all subjects, but only in four fast acetylators was there a concomitant increase in antipyrine elimination. In the four slow acetylators antipyrine metabolism was inhibited after the first dose of the drugs. In nine tuberculous patients followed serially there was a fall in 25‐OHD and 1,25 (OH) 2 D and a rise in PTH at the end of 1 mo (P < 0.05). After 6 mo therapy 25‐OHD concentration was further reduced (P < 0.01), but there was now no significant change in 1,25 (OH) 2 D or PTH levels. Combination treatment with rifampicin and isoniazid perturbs vitamin D metabolism, but less than might have been predicted from reports on each drug given alone. Nevertheless, tuberculous patients with already compromised calcium homeostasis receiving this combination of drugs should be carefully monitored. Clinical Pharmacology and Therapeutics (1982) 32 , 525–530; doi: 10.1038/clpt.1982.197